On March 18, 2024, AbbVie Inc. filed a definitive proxy statement soliciting proxies and urged the shareholders to vote against a shareholder proposal, requesting that the board take each step necessary so that each voting requirement in the Company charter and bylaws (that is explicit or implicit due to default to state law) that calls for a greater than simple majority vote be replaced by a requirement for a majority of the votes cast for and against applicable proposals, or a simple majority in compliance with applicable laws. If necessary this means the closest standard to a majority of the votes cast for and against such proposals consistent with applicable laws. This includes making the necessary changes in plain English, submitted by John Chevedden, on behalf of Kenneth Steiner, at the Company?s annual shareholders meeting scheduled to be held on May 3, 2024.